pomalidomide has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambinder, R; Cheever, M; Ekwede, I; George, J; Goncalves, PH; Gulley, JL; Lurain, K; Mangusan, R; Ramaswami, R; Uldrick, TS; Wang, HW; Widell, A; Yarchoan, R | 1 |
| Wiernik, PH | 1 |
| Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I | 1 |
| Czuczman, MS; Hernandez-Ilizaliturri, FJ; Holkova, B; Ottman, E; Reddy, N | 1 |
| Corral, LG; Fleming, YW; Stein, B; Zhu, D | 1 |
2 review(s) available for pomalidomide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia | 2011 |
3 other study(ies) available for pomalidomide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; HIV Infections; Humans; Immune Checkpoint Inhibitors; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Thalidomide; Time Factors | 2021 |
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Mice; Mice, SCID; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Neoplasms; Prostatic Neoplasms; Thalidomide | 2008 |